The use of anti-inflammatory medications in cystic fibrosis: Trends and physician attitudes

Chest

Volumn 115, Issue 4, 1999, Pages 1053-1058

  Oermann, Christopher M ^a   Sockrider, Marianna M ^a   Konstan, Michael W ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Corticosteroids; Ibuprofen; Prescribing patterns

Indexed keywords

CORTICOSTEROID; IBUPROFEN;

ARTICLE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; STEROID THERAPY;

EID: 0032931961     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.4.1053     Document Type: Article

References (19)

1. 1 Davis PB, Drumm M, Konstan MW. Cystic fibrosis: state of the art. Am J Respir Crit Care Med 1996; 154:1229-1256
2. 2 Konstan MW, Berger M. Infection and inflammation in the lung in cystic fibrosis. In: Davis PB, ed. Cystic fibrosis. New York, NY: Marcel Dekker, 1993
3. 3 Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis-onset and etiology. Pediatr Pulmonol 1997; 24:137-142
4. 4 Eigen H, Rosenstein BJ. A multicenter study of alternate day prednisone in patients with cystic fibrosis. J Pediatr 1995; 126:515-523
5. 5 Rosenstein BJ, Eigen H. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 1991; 87:245-246
6. 6 Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332:848-854
7. 7 Nikolaizik WH, Schöni MH. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr 1996; 128:271-274
8. 8 Van Haren EHJ, Lammers J-WJ, Festen J, et al. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med 1995; 89:209-214
9. 9 Balfour-Lynn IM, Klein NJ, Dinwiddie R. Randomized controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 1997; 77:124-130
10. 10 Konstan MW. Treatment of airway inflammation in cystic fibrosis. Curr Opin Pulm Med 1996; 2:452-456
11. 11 Cystic Fibrosis Foundation. Patient registry 1996 annual data report. Bethesda, MD: Cystic Fibrosis Foundation, August 1997
12. 12 Auerbach HS, Williams M, Kirkpatrick JA, et al. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2:686-688
13. 13 Donati MA, Haver K, Gerson W, et al. Long-term alternate day prednisone therapy in cystic fibrosis. Pediatr Pulmonol 1990; suppl 5:277
14. 14 Konstan MW, Hoppel CL, Chai B, et al. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse events. J Pediatr 1991; 118:956-964
15. 15 Oermann CM, Sockrider MM, Murry DJ. One year's experience with high-dose ibuprofen. Pediatr Pulmonol 1996; Suppl 13:280-281
16. 16 Kovesi TA, Swartz R, MacDonald N. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. N Engl J Med 1998; 338:65-66
17. 17 North American Cystic Fibrosis Foundation. Ibuprofen: information for cystic fibrosis physicians. Bethesda, MD: Cystic Fibrosis Foundation, 1995
18. 18 Konstan MW, FitzSimmons SC. Clinical use of ibuprofen for cystic fibrosis (CF) lung disease: data from the 1996 CF Foundation National Patient Registry. Pediatr Pulmonol 1997; Suppl 14:322
19. 19 Schmidt J, Davidson AGF, Seer M, et al. Is the acquisition of pseudomonads in cystic fibrosis patients increased by use of inhaled corticosteroids? Unexpected results from a double blind placebo controlled study. Pediatr Pulmonol 1997; 14(suppl):293-294